Sigma Pharmaceuticals warns of asset writedowns, dividend cut
Sigma Pharmaceuticals has warned of asset writedowns and a dividend cut as it faces tough competition in the generic drugs market in Australia.
US banking giant JPMorgan Chase said on Monday it was drastically cutting its dividend payments to shareholders to save an estimated US$5 billion in capital per year.